2022--provirex--hamburg-researchers-want-to-be-able-to-cure-hiv-soon---magazine--healty-and-sport-news (Working | Workflow)

Research published in Nature Biotechnology demonstrated that Brec1 can target and excise over 90% of clinical HIV-1 isolates found globally.

In October 2022, PROVIREX announced a major expansion in Hamburg’s .

Preclinical data showed the enzyme has no measurable cytotoxic or genotoxic side effects, making it a viable candidate for human testing. 3. 2022 Milestones: The Hamburg Therapy Hub